A Structured Review and Guide Through Studies on Health-Related Quality of Life in Kidney Cancer, Hepatocellular Carcinoma, and Leukemia

REFERENCES

• National Cancer Institute. Costs of Cancer Care, Cancer Trends Progress Report. Bethesda, MD: National Cancer Institute, 2007.
   Google Scholar
• Food and Drug Administration (FDA). Guidance for Industry: Patient-Reported Outcome Measures Used in Medical Product Development to Support Labeling Claims, Draft Guidance. Available at: http://www.fda.gov/cber/gdlns/prolbl.htm (accessed on Feb 11, 2009).
   Google Scholar
• American Cancer Society. Cancer Facts and Figures. Atlanta, GA: ACS, 2008.
   Google Scholar
• Dimitroulopoulos, D.; Xinopoulos, D.; Tsamakidis, K.; Long-acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors: randomized placebo-controlled trial. World J Gastroenterol 2007, 13(23), 3164–3170.
   PubMed Web of Science ®Google Scholar
• El-Serag, H. B. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004, 127, S27–S34.
   PubMed Web of Science ®Google Scholar
• Tengs, T.O.; Wallace, A. One thousand health-related quality-of-life estimates. Med Care 2000, 38, 583–637.
   PubMed Web of Science ®Google Scholar
• Garratt, A.; Schmidt, L.; Mackintosh, A.; Fitzpatrick, R. Quality of life measurement: bibliographic study of patient assessed health outcome measures. BMJ 2002, 324, 1417.
   PubMed Web of Science ®Google Scholar
• Heinzer, H.; Mir, T.S.; Huland, E.; Huland, H. Subjective and objective prospective, long-term analysis of quality of life during inhaled interleukin-2 immunotherapy. J Clin Oncol 1999, 17, 3612–3620.
   PubMed Web of Science ®Google Scholar
• Motzer, R.J.; Murphy, B.A.; Bacik, J.; Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol 2000, 18, 2972–2980.
   PubMed Web of Science ®Google Scholar
• Dutcher, J.P.; Logan, T.; Gordon, M.; Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study. Clin Cancer Res 2000, 6, 3442–3450.
   PubMed Web of Science ®Google Scholar
• Tannir, N.M.; Cohen, L.; Wang, X.; Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell carcinoma. Cancer 2006, 107, 2254–2261.
   PubMed Web of Science ®Google Scholar
• Negrier, S.; Perol, D.; Ravaud, A.; Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial. Cancer 2007, 110, 2468–2477.
   PubMed Web of Science ®Google Scholar
• Motzer, R.J.; Michaelson, M.D.; Redman, B.G.; Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006, 24, 16–24.
   PubMed Web of Science ®Google Scholar
• Motzer, R.J.; Hutson, T.E.; Tomczak, P.; Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356, 115–124.
   PubMed Web of Science ®Google Scholar
• Cella, D.; Li, J.Z.; Cappelleri, J.C.; Bushmakin, A.; Charbonneau, C.; Kim, S.T.; Chen, I.; Motzer, R.J. Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial. J Clin Oncol 2008 ( Aug 1), 26(22), 3763–3769.
   PubMed Web of Science ®Google Scholar
• Kouroumalis, E.; Skordilis, P.; Thermos, K.; Vasilaki, A.; Moschandrea, J.; Manousos, O.N. Treatment of hepatocellular carcinoma with octreotide: a randomized controlled study. Gut 1998, 42, 442–447.
   PubMed Web of Science ®Google Scholar
• Yuen, M.F.; Poon, R.T.; Lai, C.L.; A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. Hepatology 2002, 36, 687–691.
   PubMed Web of Science ®Google Scholar
• Becker, G.; Allgaier, H.P.; Olschewski, M.; Zähringer, A.; Blum, H.E.; HECTOR study group. long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study. Hepatology 2007, 45, 9–15.
   PubMed Web of Science ®Google Scholar
• Verset, G.; Verslype, C.; Reynaert, H.; Efficacy of the combination of long-acting release octreotide and tomoxiifen in patients with advanced hepatocellular carcinoma: a randomized multicentre phase III study. Br J Cancer 2007, 97, 582–588.
   PubMed Web of Science ®Google Scholar
• Chow, P.K.; Tai, B.C.; Tan, C.K.; High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: a multicenter randomized controlled trial. Hepatology 2002, 36, 1221–1226.
   PubMed Web of Science ®Google Scholar
• Barbare, J.C.; Bouché, O.; Bonnetain, F.; Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma. J Clin Oncol 2005, 23, 4338–4346.
   PubMed Web of Science ®Google Scholar
• Steel, J.; Baum, A.; Carr, B. Quality of life in patients diagnosed with primapry hepatocellular carcinoma: hepatic arterial infusion of cisplatin versus 90-yttrium microspheres (therasphere). Psychooncology 2004, 13, 73–79.
   PubMed Web of Science ®Google Scholar
• Yeo, W.; Mo, F.K.; Koh, J.; Quality of life is predictive of survival in patients with unresctable hepatocellular carcinoma. Ann Oncol 2006, 17, 1083–1089.
   PubMed Web of Science ®Google Scholar
• Brans, B.; Lambert, B.; De Beule, E.; Quality of life assessment in radionuclide therapy: a feasibility study of the EORTC QLQ-C30 questionnaire in palliative 131I-lipiodol therapy. Eur J Nucl Med Mol Imaging 2002, 29, 1374–1379.
   PubMed Web of Science ®Google Scholar
• Wang, Y.B.; Chen, M.H.; Yan, K.; Yang, W.; Dai, Y.; Yin, S.S. Quality of life after radiofrequency ablation combined with transcatheter arterial chemoembolization for hepatocellular carcinoma: comparison with transcatheter arterial chemoembolization alone. Qual Life Res 2007, 16, 389–397.
   PubMed Web of Science ®Google Scholar
• Rossi, J.F.; van Hoof, A.; de Boeck, K.; Efficacy and safety of oral fludarabine phosphate in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2004, 22, 1260–1267.
   PubMed Web of Science ®Google Scholar
• Holzner, B.; Kemmler, G.; Kopp, M.; Quality of life of patients with chronic lymphocytic leukemia: results of a longitudinal investigation over 1 yr. Eur J Haematol 2004, 72, 381–389.
   PubMed Web of Science ®Google Scholar
• Shanafelt, T.D.; Bowen, D.; Venkat, C.; Quality of life in chronic lymphocytic leukemia: an international survey of 1482 patients. Br J Haematol 2007, 139, 255–264.
   PubMed Web of Science ®Google Scholar
• Littlewood, T.J.; Bajetta, E.; Nortier, J.W.; Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001, 19, 2865–2874.
   PubMed Web of Science ®Google Scholar
• Österborg, A.; Brandberg, Y.; Molostova, V.; Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies. J Clin Oncol 2002, 20, 2486–2494.
   PubMed Web of Science ®Google Scholar
• Hahn, E.A.; Glendenning, G.A.; Sorensen, M.V.; Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS study. J Clin Oncol 2003, 21, 2138–2146.
   PubMed Web of Science ®Google Scholar
• Kluin-Nelemans, H.C.; Buck, G.; le Cessie, S.; Randomized comparison of low-dose versus high-dose interferon-alfa in chronic myeloid leukemia: prospective collaboration of 3 joint trials by the MRC and HOVON groups. Blood 2004, 103, 4408–4415.
   PubMed Web of Science ®Google Scholar
• Persson, L.; Larsson, G.; Ohlsson, O.; Hallberg, I.R. Acute leukemia or highly malignant lymphoma patients' quality of life over two years: a pilot study. Eur J Cancer Care 2001, 10, 36–47.
   PubMed Web of Science ®Google Scholar
• Kornblith, A.B.; Herndon, J.E.; Silverman, L.R.; Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a cancer and leukemia group B study. J Clin Oncol 2002, 20, 2441–2452.
   PubMed Web of Science ®Google Scholar
• Kantarjian, H.; Issa, J.P.; Rosenfeld, C.S.; Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006, 106, 1794–1803.
   PubMed Web of Science ®Google Scholar
• Eiser, C.; Vance, Y.H.; Glaser, A.; Growth hormone treatment and quality of life among survivors of childhood cancer. Horm Res 2005, 63, 300–304.
   PubMed Web of Science ®Google Scholar
• Sheppard, L.; Eiser, C.; Davies, H.A.; The effects of growth hormone treatment on health-related quality of life in children. Horm Res 2006, 65, 243–249.
   PubMed Web of Science ®Google Scholar
• Reinfjell, T.; Lofstad, G.E.; Veenstra, M.; Vikan, A.; Diseth, T.H. Health-related quality of life and intellectual functioning in children in remission from acute lymphoblastic leukemia. Acta Paediatr 2007, 96, 1280–1285.
   PubMed Web of Science ®Google Scholar
• Link, K.; Moëll, C.; Osterberg, K.; Persson, R.; Adult survivors of childhood acute lymphoblastic leukemia with GH deficiency have normal self-rated quality of life but impaired neuropsychological performance 20 years after cranial irradiation. Clin Endocrinol (Oxf) 2006, 65, 617–625.
   PubMed Web of Science ®Google Scholar
• Brooks, R. EuroQol: the current state of play. Health Policy 1996, 37, 53–72.
   PubMed Web of Science ®Google Scholar
• Mor, V.; Labiberte, L.; Morris, J.N.; Wiemann, M. The Karnofsky performance status scale. An examination of its reliability and validity in a research setting. Cancer 1984, 53, 2002–2007.
   PubMed Web of Science ®Google Scholar
• Ware, J.E.; Sherbourne, C.D. The MOS 36-item short-form health survey (SF-36): I. conceptual framework and item selection. Medical Care 1992, 30, 473–483.
   PubMed Web of Science ®Google Scholar
• Ware, J.E.; Snow, K.K.; Kosinski, M.K.; SF-36 Health Survey Manual and Interpretation Guide. Boston, MA: Nimrod Press, 1993.
   Google Scholar
• Nordbeck, B.; Hagberg, B.; Jadbeck, G.; Stroke patients in Sweden. Paper presented at the Fifteenth World Congress of Genrontology, Budapest, Hungary, 1992.
   Google Scholar
• Antonovsky, A. The structure and properties of the sense of coherence scale. Soc Sci Med 1993, 36, 725–733.
   PubMed Web of Science ®Google Scholar
• Varni, J.W.; Seid, M.; Kurtin, P.S. PedsQL 4.0: reliability and validity of the pediatric quality of life inventory version 4.0 generic core scales in healthy and patient populations. Med Care 2001, 39, 800–812.
   PubMed Web of Science ®Google Scholar
• Aaronson, N.K.; Ahmedzai, S.; Bergman, B.; The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993, 85, 365–376.
   PubMed Web of Science ®Google Scholar
• Cella, D.F.; Tulsky, D.S.; Gray, G.; The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol 1993, 11, 570–579.
   PubMed Web of Science ®Google Scholar
• Spitzer, W.O.; Dobson, A.J.; Hall, J.; Measuring the quality of life of cancer patients: a concise QL-index for use by physician. J Chronic Dis 1981, 34, 585–597.
   PubMedGoogle Scholar
• Heffernan, N.; Cella, D.; Webster, K.; Health-related quality of life in patients with hepatobiliary cancers: the functional assessment of cancer therapy-hepatobiliary questionnaire. J Clin Oncol 2002, 20, 2229–2239.
   PubMed Web of Science ®Google Scholar
• Sutherland, H.J.; Walker, P.; Till, J.E. The development of a method for determining oncology patients' emotional distress using linear analogue scales. Cancer Nurs 1988, 11, 303–308.
   PubMed Web of Science ®Google Scholar
• Bacik, J.; Mazumdar, M.; Murphy, B.A.; The functional assessment of cancer therapy-BRM (FACT-BRM): a new tool for the assessment of quality of life in patients treated with biologic response modifiers. Qual Life Res 2004, 13, 137–154.
   PubMed Web of Science ®Google Scholar
• Yellen, S.B.; Cella, D.F.; Webster, K.; Blendowski, C.; Kaplan, E. Measuring fatigue and other anemia-related symptoms with the functional assessment of cancer therapy (FACT) measurement system. J Pain Symptom Manage 1997, 13, 63–74.
   PubMed Web of Science ®Google Scholar
• Cella, D.; Yount, S.; Du, H.; Development and validation of the functional assessment of cancer therapy-kidney symptom index (FKSI). J Support Oncol 2006, 4, 191–199.
   PubMedGoogle Scholar
• McCorkle, R. The measurement of symptom distress. Semin Oncol Nurs 1987, 3, 248–256.
   PubMedGoogle Scholar
• McCorkle, R.; Young, K. Development of a symptom distress scale. Cancer Nurs 1978, 1, 373–378.
   PubMedGoogle Scholar
• Radloff, L.S. The use of the center or epidemiologic studies depression scale in adolescents and young adults. J Youth Adolesc 1977, 20, 149–166.
   Google Scholar
• Cella, D. The functional assessment of cancer therapy-anemia (FACT-An) scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 1997, 34, 13–19.
   PubMed Web of Science ®Google Scholar
• Mendoza, T.R.; Wang, X.S.; Cleeland, C.S.; The rapid assessment of fatigue severity in cancer patients: use of the brief fatigue inventory. Cancer 1999, 85, 1186–1196.
   PubMed Web of Science ®Google Scholar
• Veit, C.T.; Ware, J.E. The structure of psychological distress and well-being in general populations. J Consult Clin Psychol 1983, 51, 730–742.
   PubMed Web of Science ®Google Scholar
• Derogatis, L.R. SCL-90-R, Administration, Scoring and Procedures Manual I for the Revised Version of the SCL-90. Baltimore, MD: Johns Hopkins University Press, 1977.
   Google Scholar
• McKenna, S.; Doward, L.C.; Alonso, J.; The QoL-AGHDA: an instrument for the assessment of quality of life in adults with growth hormone deficiency. Qual Life Res 1999, 8, 373–383.
   PubMed Web of Science ®Google Scholar
• Blazeby, J.M.; Currie, E.; Zee, B.C.; Development of a questionnaire module to supplement the EORTC QLQ C-30 to assess quality of life in patients with hepatocellular carcinoma, the EORTC QLQ-HCC18. Eur J Cancer 2004, 40, 2439–2444.
   PubMed Web of Science ®Google Scholar
• Steel, J.L.; Eton, D.T.; Cella, D.; Olek, M.C.; Carr, B.I. Clinically meaningful changes in health-related quality of life in patients diagnosed with hepatobiliary carcinoma. Ann Oncol 2006, 17, 304–312.
   PubMed Web of Science ®Google Scholar
• Eton, D.T.; Cella, D.; Bacik, J.; Motzer, R.J. A brief symptom index for advanced renal cell carcinoma. Health Qual life Outcomes 2006, 26(4), 68.
   Google Scholar
• Cella, D.; Yount, S.; Brucker, P.S.; Development and validation of a scale to measure disease-related symptoms of kidney cancer. Value Health 2007, 10, 285–293.
   PubMed Web of Science ®Google Scholar
• Harding, G.; Cella, D.; Robinson, D., Jr; Mahadevia, P.J.; Clark, J.; Revicki, D.A. Symptom burden among patients with renal cell carcinoma (RCC): content for a symptom index. Health Qual Life Outcomes 2007, 14(5), 34.
   Google Scholar
• Zittoun, R.; Achard, S.; Ruszniewski, M. Assessment of quality of life during intensive chemotherapy or bone marrow transplantation. Psychooncology 1999, 8, 64–73.
   PubMed Web of Science ®Google Scholar
• Zittoun, R.; Suciu, S.; Watson, M.; Quality of life in patients with acute myelogenous leukemia in prolonged first complete remission after bone marrow transplantation (allogeneic or autologous) or chemotherapy: a cross-sectional study of the EORTC-GIMEMA AML 8A trial. Bone Marrow Transplant 1999, 20, 307–315.
   Web of Science ®Google Scholar
• Holzner, B.; Bode, R.K.; Hahn, E.A.; Equating EORTC QLQ-C30 and FACT-G scores and its use in oncological research. Eur J Cancer 2006, 42, 3169–3177.
   PubMed Web of Science ®Google Scholar
• Marquis, P.; Chassany, O.; Abetz, L. A comprehensive strategy for the interpretation of quality-of-life data based on existing methods. Value Health 2004, 7, 93–104.
   PubMed Web of Science ®Google Scholar
• Pickard, A.S.; Topfer, L.A.; Feeny, D.H. A structured review of studies on health-related quality of life and economic evaluation in pediatric acute lymphoblastic leukemia. J Natl Cancer Inst Monogr 2004, 33, 102–125.
   PubMedGoogle Scholar